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Abstract
Background
Despite the widespread implementation of the pneumococcal conjugate vaccine, Strepto-
coccus pneumoniae remains the leading cause of severe pneumonia associated with mor-
tality among children less than 5 years of age worldwide, with the highest mortality rates
recorded in Africa and Asia. However, information on the effectiveness and prevalence of
vaccine serotypes post-roll out remains scarce in most African countries. Hence, this sys-
tematic review aimed to describe what is known about the decline of childhood invasive
pneumococcal disease post-introduction of the pneumococcal conjugate vaccine in Africa.
Methods
This systematic review included articles published between 2009 and 2018 on the imple-
mentation of the pneumococcal conjugate vaccine in Africa. We searched PubMed, Scopus
and African Index Medicus for articles in English. Studies on implementation programmes of
pneumococcal conjugate vaccine 10/13, with before and after data from different African
countries, were considered eligible. The review followed the procedures published in PROS-
PERO (ID = CRD42016049192).
Results
In total, 2,280 studies were identified through electronic database research, and only 8 stud-
ies were eligible for inclusion in the final analysis. Approximately half (n = 3) of these studies
were from South Africa. The overall decline in invasive pneumococcal disease ranged from
31.7 to 80.1%. Invasive pneumococcal diseases caused by vaccine serotypes declined sig-
nificantly, the decline ranged from 35.0 to 92.0%. A much higher decline (55.0–89.0%) was
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found in children below 24 months of age. Of all vaccine serotypes, the relative proportions
of serotypes 1, 5 and 19A doubled following vaccine roll out.
Interpretation
Following the introduction of the pneumococcal conjugate vaccine, a significant decline was
observed in invasive pneumococcal disease caused by vaccine serotypes. However, data
on the effectiveness in this region remain scarce, meriting continued surveillance to assess
the effectiveness of pneumococcal vaccination to improve protection against invasive pneu-
mococcal disease.
Introduction
Streptococcus pneumoniae is a Gram-positive bacterium that asymptomatically colonizes the
upper respiratory tract. The colonization rate is 3 times higher in populations living in low and
middle income countries (LMICs) (85.0%) compared to those living in high income countries
(27.0%) and is higher in children under five years of age compared to adults [1]. Studies have
shown that a high colonization rate is a risk for developing an infection. Pneumococcal infec-
tions are acquired through aspiration of droplets, leading to pneumonia with or without bac-
teraemia [2,3]. Approximately 18.0% of all severe pneumonia infections in children less than 5
years of age are caused by S. pneumoniae, which makes it the second most common cause of
severe pneumonia after respiratory syncytial virus. However, it is the leading cause of pneumo-
nia mortality in children less than five years of age (32.7%) [4].
Over 97 different pneumococcal serotypes have currently been identified [5], and their dis-
tributions vary widely. The serotype distribution is affected by a number of factors, such as age
and geographical location [1]. Worldwide, in the vaccine era, the most common serotype is 14,
accounting for 19–26% of all invasive pneumococcal disease (IPD). In LMICs, serotypes 1, 5
and 14 cause more than 30.0% of all IPD [6]. However, in children less than 2 years of age,
serotypes 6A, 6B 14, 19F and 23F are the most common, while serotypes 1, 6B, 14, 18C and
23F are the most prevalent in children 2 to 5 years of age. According to Pilishvili and colleagues
in the US, serotypes 6, 14, 18 and 19 are the most common serotypes among children below
the age of 2 years [7].
Different vaccines have been developed to reduce or eliminate the burden of infections
caused by S. pneumoniae. Currently, two types of vaccines are recommended by the WHO,
including the unconjugated 23-valent polysaccharide vaccine (PPSV) and the 10- or 13-valent
conjugated polysaccharide vaccine (PCV) [7,8]. The WHO recommends the use of 10- or
13-valent in national immunization programmes, and countries can choose either one of the
PCVs to include in their programme, which generally depends on the national epidemiology
of S. pneumoniae serotypes and the cost [1]. The serotypes covered by 10-valent vaccines are 1,
4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F. In addition to these, the 13-valent vaccine contains sero-
types 3, 6A and 19A. These serotypes account for more than 70.0% of all S. pneumonia-associ-
ated IPD based on epidemiological data collected in Western countries [6].
Through the support of the Global Alliance for Vaccination and Immunization (Gavi),
most African countries have been able to implement the WHO recommendation of including
pneumococcal vaccines in national immunization programmes, with Rwanda being the first
African country to roll out PCV13 in 2009. By March 2018, of the 73 Gavi eligible countries 59
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(81%) had adopted the WHO recommendation [9]. However, the full roll out is still a chal-
lenge to some countries in Africa.
Reduction of pneumococcal carriage and IPD, including pneumonia incidence, caused by
vaccine types (VT) has been reported [10]. Inversely, there is evidence of a significant increase
in non-vaccine type (NVT) carriage [11]. Some of these NVT have been reported to cause IPD
but with a lower-case fatality rate. Furthermore, the protective efficacy against serotype 3
induced by the 13-valent vaccine has been shown to be very limited [12].
The impact of PCV 10/13 on the reduction of IPD and pneumonia is crucial for successful
implementation. Although data remain scarce even ten years after the implementation of PCV
in Africa, different studies have been conducted in Kenya, Burkina Faso, Morocco, the Gam-
bia, Mozambique, and South Africa, and a clear overview of the current situation is lacking.
Therefore, there is a need to gather all available information on the prevalence of VT and on
serotype distribution post-roll out of PCV 10/13 in Africa. In addition, surveillance of the
highly prevalent serotypes is an important priority.
Objectives
This systematic review was conducted to estimate the decline of invasive pneumococcal disease
among children under five years of age following the introduction of 10 and 13-valent in
Africa. In addition, the serotype distribution was compared pre- and post-PCV enrolment.
Methods
The study protocol development was guided by preferred reporting items for systematic review
and meta-analysis, as mentioned in the PRISMA check list (S1 PRISMA check list) [13]. The sys-
tematic review protocol was registered in PROSPERO under number CRD42016049192 (avail-
able at https://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42016049192).
Eligibility criteria
Studies in children under five years of age conducted in Africa were eligible for inclusion.
Additionally, studies that recruited all ages but with stratified data on children less than 5 years
of age were included. Studies from countries with either of the two available vaccines (10- and
13-valent) were included, irrespective of the immunization schedules and vaccine coverage.
Publications were excluded based on the following criteria: studies without age-specific
data, systematic review articles and studies without data on either pre- or post-PCV introduc-
tion. Studies from countries that have yet to roll out PCV and studies without serotype-specific
data were not eligible.
Literature research
We conducted a systematic literature search of published studies on S. pneumoniae infection.
We searched the following electronic databases: PubMed, Scopus, and African Index Medicus
(AIM) for studies published between 2009 and 2018. The search was limited to publications in
English and used the following key words: S. pneumoniae carriage, IPD, serotypes, 10-valent
and 13-valent vaccine and Africa. We also used the Medical subject heading (MeSH) database
to identify synonyms of the subject keywords. The full search strategy is available in the S1
Search strategy (PubMed & Scopus).
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Data collection and quality assessment
The results of the searches were all imported into Covidence (https://www.covidence.org/),
and JSN performed an automatic check to exclude duplicate entries. The process was followed
by screening titles to exclude all irrelevant studies independently by two reviewers (JSN and
BTM). In this process of abstract screening, the reviewers either included, excluded or classi-
fied abstracts as ‘maybe’. The reviewers met to discuss the disagreements, with a consensus to
include or exclude. The same procedure was followed for the full-text screening. The reviewers
provided the reasons for excluding studies at this stage. The final included studies for data
extraction and the screening process created by Covidence are presented here as part of the
PRISMA study flow diagram (Fig 1) [14].
We modified the Cochrane data extraction form [15] and developed an Excel spreadsheet
form for this systematic review. We extracted the following information: country, design (start
and end date for data collection, duration of participation), study population (eligibility crite-
ria and method of recruitment, total number enrolled, co-morbid infections), outcomes (out-
come name, time point measured, outcome definition), and results (comparison, outcome,
baseline data, unit of analysis, and method of analysis). Furthermore, we extracted information
related to PCV roll out, serotype, country vaccination coverage and participants’ vaccination
status.
Fig 1. Study selection process.
https://doi.org/10.1371/journal.pone.0212295.g001
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The risk of bias in cross-sectional studies was assessed using the Newcastle-Ottawa scale
(NOS). The NOS is commonly used in the evaluation of evidence in non-randomized studies
[16,17]. For studies assessing the effectiveness before and after vaccination, the National Insti-
tute for Health checklist was used to assess the risk of bias [18]. A detailed risk of bias assess-
ment is presented in S1 Risk of bias assessment for effectiveness.
Data analysis
In this review, the primary outcome was IPD caused by vaccine-specific serotypes. We pro-
vided a narrative synthesis of the findings because of the significant variations between the
included studies regarding the design, vaccine coverage, vaccination status, and outcome mea-
surements as well as with respect to the period between PCV roll out and the start of data col-
lection. There was significant variability in the design and recruitment methods, which made
it inappropriate to conduct a meta-analysis.
The vaccine-dependent decline in IPD cases was calculated in two different ways depending
on the outcome measure: as the percentage change in the relative proportion of PCV serotypes
[(pre-PCV proportion–post-PCV proportion)/pre-PCV proportion [19]] or as the percentage
relative risk difference (RR), the ratio of the probability of developing pneumococcal disease
occurring in the vaccinated (post-PCV) to the non-vaccinated group (before introduction of
PCV), or odds ratio (OR) before and after vaccination. The decline was calculated using the
formula: 1-OR or 1- RR [19].
Results
Identification of eligible PCV vaccination studies
In total, 2,280 research articles were identified during the electronic database search. Eight
research articles were eligible for inclusion into the final analysis (Fig 1). Of the eight included
articles, three were from South Africa. Of the included countries, three used the 13-valent vac-
cine, while three countries used the 10-valent vaccine. Five of the included studies had no data
collection interruption during the study period starting the year before and extending to the
years after the introduction of the vaccine. Six of the included studies assessed the serotypes
using routinely collected samples for pneumococcus surveillance (Table 1) [20–23].
Decline in IPD caused by vaccine serotypes
Several studies reported the decline of IPD by age categories [21–26], while von Mollendorf
and colleagues reported an overall vaccine decline among children under the age of 5 without
age stratification data on the age category [27]. Von Gottberg and colleagues reported disease
reduction due to vaccine types, covered by 7- and 13-valent [21]. Diawara et al. (2015) con-
ducted the same analysis and reported on disease caused by VT (7- and 10-valent) and NVT.
The decline varied, with some studies having a wide confidence interval for the effect esti-
mate (Table 2). Regardless of the vaccine type, serotypes, study design, time period between
vaccine roll out to data collection and difference in age groups, the decline ranged from 31.7 to
80.1%. Invasive pneumococcal diseases caused by vaccine serotypes declined significantly, the
decline ranged from 35.0 to 92.0%. A much higher decline (55.0–89.0%) was found in children
below 24 months of age. One study reported a non-significant percentage increase in relative
risk (4.5%, 95%CI = -52.3 to 128.9) [22].
For PCV7 serotypes, the overall decline ranged from 56.1 to 91.7% and 53.7 to 74.0%
among children less than 24 months and above 24 months, respectively [21,22,24–26]. A
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stronger decline in PCV7 serotypes was found in studies that used “percentage relative differ-
ence in the rate” as the effect estimate. The decline ranged from 63.8 to 91.7% [26].
Two studies estimated the decline in 10-valent vaccine serotypes; in these studies, the per-
centage relative risk reduction was 84.2 and 92.0% [25,28]. For the three additional 10-valent
vaccine specific serotypes (PCV10-nonPCV7 serotypes), significant reductions ranging from
28.1 to 77.7% were recorded among younger children [22,25]. However, among children aged
24–59 months, the decline in IPD was non-significant [22].
Of the included studies, three found a reduction of IPD caused by the 13-valent serotypes,
which ranged from 58.0 to 82.0% [24,26]. Furthermore, for children older than two years, the
decline was reported to be 68.0% [24]. Two of the included studies estimated a decline for the
three additional serotypes present in the 13-valent vaccine and not in the PCV-10 vaccine (3,
6A and 19A). The authors described a significant decline in the rates of IPD for serotypes 3,
6A and 19A. The reported reduction ranged between 22.0 and 82.0% [21,24].
Relative proportion of vaccine serotypes
Of the total of 2,001 pneumococcal vaccine strains isolated in different countries in different
clinical studies conducted in Africa, 1,317 and 684 were isolated before and after the vaccine
roll out, respectively. Before the vaccine roll out, the three most common serotypes were 14
(16.5%, n = 271), followed by 19A (13.7%, n = 180) and 6A (13.0%, n = 171) (Fig 2). Following
Table 1. Characteristics of the studies included in the review.
Author Country PCV Introduction
year
Reported
coverage %
Study period Study design Identification method
Von Gottberg et al.,
2014 [21]
South Africa 13 PCV7–2009
PCV13–2011
2009–10
2012–81
Before:
2005–2008
After: 2011–
2012
Before and after vaccine
Laboratory surveillance
Culture
Diawara et al., 2015
[22]
Casablanca,
Morocco
10 PCV13–2010
Pcv10–2012
2014–88 Before:
2007–2010
After: 2011–
2014
Before and after vaccine
Laboratory surveillance
Culture
Mackenzie et al., 2016
[24]
The Gambia 13 August 2009 –
PCV13
June 2011 –
PCV10
2010–35
2013–94
Before:
2008–2010
After: 2013–
2014
Before and after vaccine
Population surveillance
Culture
Von Mollendorf
et al., 2016 [27]
South Africa 13 PCV7–2009
PCV13–2011
2009–10
2013–62
Before:
2003–2010
After: 2011–
2013
Before and after vaccine
Laboratory surveillance
Culture and PCR
Tempia et al., 2015
[26]
Soweto, South
Africa
13 PCV7–2009
PCV13–2011
2009–10
2012–81
Before: 2009
After: 2011–
2012
Before and after vaccine
Laboratory surveillance
Culture and PCR
Nhantumbo et al.,
2017 [25]
Mozambique
(3-regions)
10 March 2013 97 Before: 2013
After: 2014–
2015
Before and after vaccine
Laboratory surveillance
Culture and PCR
Hammitt et al., 2018
[28]
Kilifi Kenya 10 January 2011 2011–80
2017–84
Before:
1999–2010
After: 2012–
2016
Before and after vaccine
hospital surveillance
Culture, latex & quelling
reaction confirmed by PCR
Kambire et al., 2018
[23]
Burkina Faso 13 October 2013 2015–105% Before:
2011–2013
After: 2014–
2015
Before and after vaccine
Laboratory surveillance
Culture and latex
93.4%-confirmed by PCR
https://doi.org/10.1371/journal.pone.0212295.t001
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Table 2. Effectiveness of PCV in the prevention of IPD among children under five years of age.
Von Gottberg et al.,
2014 [21]
Diawara
et al.,
2015 [22]
Mackenzie
et al., 2016
[24]
Tempia et al., 2015[26] Nhantumbo
et al., 2017
[25]
Von
Mollendorf
et al., 2016
[27]
Kambire et al., 2018 [23] Hammitt
et al.,
2018 [28]
Age &
serotypes
Baseline
to 2011
Relative
difference
in rate %
(95%CI)
Baseline
to 2012
Relative
difference
in rate %
(95%CI)
Relative
risk
reduction
% (95%
CI)
Adjusted
incidence
rate ratio
(95%CI)
Relative
difference in
hospitalization
rate
2011
Relative
difference in
hospitalization
rate
2012
Percentage
decline of
IPD
Odds ratio
2005 vs
2013
Percentage
change
(95% CI)
2014 vs.
2011–2013
Percentage
change
(95% CI)
2015 vs.
2011–2013
Adjusted
incidence
rate ratio
(95%CI)
� 24
months
All
serotypes
-60(-65 to
-56)
-69(-72 to
-65)
-60.9
(-88.1 to
-35.5)
0.45(0.29 to
0.70)
-80.1(-86.2 to
-71.8)�
-54.8(-72.6 to
-27.1)��
-64.0(-72.9 to
-52.6)�
-66.8(-81.2 to
-43.8)��
-49(-60 to
-35)
-68(-76 to
-57)
PCV7 -80(-84 to
-76)
-89(-92 to
-86)
-74.1(-100
to -40.8)
0.17(0.07 to
0.43)
-80.9(-90.9 to
-62.9)�
-83.2(-94.2 to
-59.5)��
-63.8(-79.3 to
-39.1)�
-91.7(-98.4 to
-73.6)��
56.1
6A -62(-73 to
-47)
-85(-91 to
-76)
1 -60(-81 to
-15)
-59(-81 to
-14)
Additional
PCV10
-77.7
(-93.6 to
-22.0)
28.1
PCV10 84.2
Additional
PCV 13
-22(-39 to
-1)
-57(-68 to
-42)
-85.2(-100
to 27.9)
0.18(0.06 to
0.56)
PCV 13 0.18(0.09 to
0.36)
-59.7(-85.9 to
+3.4)�
-26.3(-74.7 to
+107.3)��
+8.8(-94.8 to
+57.3)�
-63.5(-91.6 to
-26.5)��
NVT -20(-36 to
-0.2)
6(-16 to
23)
28.6
(-61.1 to
100.2)
1.48(0.70 to
3.13)
-82.5(-89.4 to
-72.3)�
-0.2(-58.0 to
+139.2)��
-71.7(-81.1 to
-58.5)�
+1.2(-96.7 to
+58.4)��
-15(-48 to
-38)
-69(-84 to
-39)
�24–59
months
All
serotypes
4.5(-52.3
to 128.9)
0.44(0.25 to
0.75)
PCV7 -53.7
(-81.8 to
128.0)
0.26(0.09 to
0.74)
Additional
PCV10
-3.5(-80.5
to 300.7)
Additional
PCV13
-3.5(-86.4
to 584.7)
0.38(0.17 to
0.85)
PCV 13 0.32(0.17 to
0.61)
NVT 285.8
(-56.9 to
335.2)
1.27(0.39 to
4.13)
<60
months
(Continued)
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the vaccine roll out, the common vaccine serotypes were 19A (24.3%, n = 166), followed by 6A
(16.2%, n = 111) and 1 (14.6%, n = 100).
Discussion
To the best of our knowledge, this is the first systematic review to describe the post-roll out
decline of invasive pneumococcal disease in Africa. Almost ten years post-roll out, data on the
effectiveness of the PCV vaccine remain limited in Africa. The inclusion of the few studies
Table 2. (Continued)
Von Gottberg et al.,
2014 [21]
Diawara
et al.,
2015 [22]
Mackenzie
et al., 2016
[24]
Tempia et al., 2015[26] Nhantumbo
et al., 2017
[25]
Von
Mollendorf
et al., 2016
[27]
Kambire et al., 2018 [23] Hammitt
et al.,
2018 [28]
All types -41(-55 to
-23)
-55(-66 to–
39)
0.32(0.17
to 0.60)
Serotype 1 0.12(0.02 to
0.59)
-30 (-59 to
21)
-25(-56 to
27)
PCV13 -35(-53 to
-10)
-58(-71 to
-40)
PCV10 0.08 (0.03
to 0.22)
NVT -48(-78 to
21)
-90(-92 to
-50)
1.3 (0.65
to 2.64)
�Based on PCR
��Based on culture
CI: confidence interval
https://doi.org/10.1371/journal.pone.0212295.t002
Fig 2. Relative proportion of vaccine serotypes before and after vaccine roll out. Following vaccine roll out, the
relative proportions of serotype 1 (7.4%, n = 97 vs 14.6%, n = 100), 5 (2.8%, n = 37 vs 7.5%, n = 51) and 19A (13.7%,
n = 180 vs 24.3%, n = 166) doubled compared to the baseline measurement. In contrast, a significant reduction in
serotypes 14 (6.9% vs 16.5%), 6B (7.0% vs 12.0%) and 9V (1.2% vs 2.7%) was observed.
https://doi.org/10.1371/journal.pone.0212295.g002
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from Africa in the global review underestimates the burden of IPD and might not accurately
reflect the serotype distribution post-roll out in Africa. Furthermore, some countries lack pre-
vaccine data, which makes it difficult to assess vaccine effectiveness.
Although molecular techniques have been used for decades, the common method described
in all studies in this review was pneumococcal culture. Across studies, the method used to iso-
late S. pneumoniae was not standardized according to the WHO working group recommenda-
tion [29]. Although there are no validated methods for direct serotyping of S. pneumoniae
isolates, the culture method poses a risk of underestimating vaccine effectiveness. Previous
studies have demonstrated a low sensitivity of culture methods in isolating S. pneumoniae [30].
The eligibility criteria across the included studies were different, which made it difficult to
pool the results to determine vaccine effectiveness. Of note, the design of the included studies
was different; whereas three of the included studies were based on national laboratory surveil-
lance, the other five studies were limited to a particular region. Moreover, one study was popu-
lation-based surveillance with community screening to identify children with IPD, and two
were hospital-based prospective IPD case finding. Finally, while six studies analysed the avail-
able laboratory samples, one study was a two-time point population-based cross-sectional
study (before and after).
Furthermore, different vaccines were used. Studies included in this review were conducted
in countries that implemented the 10-valent or 13-valent vaccine. In some countries, such as
South Africa, they started with PCV-7, which was later replaced by PCV-13 in 2011. Similarly,
Morocco rolled out PCV-13 in 2010, and it was replaced with PCV-10 in 2012.
Most studies identified a decline in the pneumococcal VT post-vaccine roll out in Africa,
although with a wider range. The decline shows that the serotypes included in PCV10/13 are
the culprit of more than 70% of IPD [31]. Variations in the decline are partly due to the vaccine
coverage within countries and among study participants. By the end of 2015, the PCV 10/13
coverage in Africa was estimated at 59%, which was just above the global estimate of 37% [32].
Nevertheless, even in the case of a low vaccination rate among participants, the decline was
still observed. A similar finding was reported by Oliveira and colleagues in Latin America [19].
They reported a decline that ranged from 7.4% to 84.6% among hospitalized children with
pneumonia, while they found a decline ranging from -14.7% to 66% among the IPD cases [19].
The decline in vaccine serotypes was higher among younger children compared to older
children [21,23]. Most of the included studies were conducted immediately or concurrently
with vaccine roll out. In some countries, children above the recommended age of vaccination
were given a catch-up dose at the time of vaccine roll out [20]. However, in countries such as
Gambia, PCV13 was introduced without a catch-up vaccination in children above the recom-
mended age for vaccination [24]. This means that children, especially those above two years of
age, were not vaccinated or had not completed the recommended number of doses. Moreover,
the decline in younger children is significant because the relative proportion of pneumococcal
infection is higher in this age group [1,33].
There have been declines in VT associated with IPD after introduction of the 10-valent and
13-valent PCV vaccines. Routine immunization has also influenced the carriage and associa-
tion with IPD caused by NVT [34]. We found that, after implementation of PCV10 and 13, the
relative proportion of vaccine serotypes was 33.9%. In addition, S. pneumoniae vaccine-specific
serotypes were isolated from 56.8% of children with IPD. These results are consistent (71.2%)
with findings from Latin America [35]. The percent of PCV-7 VT (27.4%) in the post-PCV era
in Africa is comparable to that reported in Europe [36].
The studies included in this review show a decline in VT causing IPD; nevertheless, approxi-
mately half of the IPD cases were caused by NVT, which has been reported previously. For
instance, in Denmark, one study reported that NVT caused 91% of IPD in children aged 0–4
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years [37]. Moreover, in a study comparing pre- and post-vaccination IPD in Barcelona, Spain,
there was an increase from 38 to 72% of NVT in children less than 5 years of age [38]. There is a
need for vaccines that are effective against many serotypes. However, data on the serotype dis-
tribution should precede the development of new vaccines. For example, efficacy studies with
PCV15 have been performed [39,40]; however, the addition of serotype 22F and 33F in PCV15
may not be advantageous for Africa since these two serotypes were only isolated in one study.
Serotype 19A has been shown to be associated with vaccine failure [41,42]. After the intro-
duction of PCV10/13 in Africa, serotype 19A became the predominant vaccine serotype. In the
pre-PCV era, serotype 19A was the sixth most prevalent serotype in children with IPD [10];
according to this review, it was the second most common vaccine serotype. The review data
show that the relative proportion of the 19A serotype doubled following vaccine roll out. Con-
versely, our findings are consistent with a recent meta-analysis by Baslells, which also found that
serotype 19A (21.6%) was the predominant serotype in children with IPD across regions [35].
These findings are believed to be due to previously reported low opsonophagocytic antibody
responses against 19A serotype evoked by PCV-13 [43]. Similar to serotype 19A, the relative
proportions of serotype 1 and 5 also doubled following vaccine roll out in African countries.
Serotype 1 is currently the third most common vaccine serotype causing IPD among children.
Of interest, serotype 6A is overall the second most common serotype in children with IPD
in Africa. Of the three-additional 13-valent serotypes (3, 6A and 19A), serotype 6A and 19A
are still the most prevalent serotypes in Africa. However, the relative proportion of serotype 3
was low, which is consistent with a previous review that also reported a low prevalence of sero-
type 3 compared to 6A and 19A among children with IPD post-PCV era [35].
The results on serotypes distribution should be interpreted with caution. First, approxi-
mately half of the included studies were from South Africa, a country that may not reflect
other parts of Africa. Secondly, some of the children recruited in these studies had not com-
pleted the recommended 3 doses. This demands continuous surveillance and notification of
the circulating serotypes in different African countries. Furthermore, to draw valid conclu-
sions on effectiveness of PCV vaccination in Africa, more and larger studies are required.
Limitations
Generally, there is a lack of uniformity in the published vaccination studies that have been con-
ducted in Africa. The study designs were different, some being population-based surveillance
while others were laboratory surveillance studies, and the methods used to identify S. pneumo-
niae were also different. This heterogeneity of the different studies and the mediocre quality of
some studies included in this review made it difficult to conduct a pooled analysis. One of
these studies had a small sample size, which might have contributed to the observed wide con-
fidence intervals in the relative differences. Additionally, no statistical tests were performed to
provide p-values for the pre-to-post changes. Furthermore, a proportion of the children
included in the studies had not received the vaccine or had not received all of the recom-
mended doses. As a result, we might have underestimated the potential decline of IPD that can
be achieved by PCV vaccination. This review included studies with different designs and dif-
ferent methods of pneumococcal detection (culture, latex and PCR), which has influenced the
reported decline in VT post-PCV roll out. In some of the included studies, no information was
available on the exact number of serotypes included in the analyses. In such cases, the number
of serotypes was calculated from proportions and sometimes extracted from figures. In addi-
tion, information on the total number of children under the age of 5 at risk was not available
in some studies and was estimated from the incidence or rates. While NVT contributed signifi-
cantly to IPD morbidity and mortality, it was not possible to conclude which NVT was most
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common as there was no uniformity in the reporting of these serotypes. We suggest perform-
ing further studies in other (currently understudied) parts of Africa to better understand the
effectiveness of PCV vaccination. More importantly, there is a strong demand for more uni-
formly conducted vaccine effectiveness studies measuring pneumococcal VT and NVT in IPD
and colonization to strengthen the conclusions on the effect of PCV implementation in Africa.
Lastly, it is unlikely that publications about relevant vaccine studies were missed in our search
as we selected articles in English. However, this limitation cannot be fully excluded consider-
ing the high number of francophone countries, particularly in west Africa.
Conclusion
After the introduction of PCV in Africa, a decline was observed in pneumococcal vaccine sero-
types among children below the age of 5 years. The strongest effects were measured in children
less than two years of age. Remarkably, the relative proportion of the three serotypes (1, 5 and
19A) of the 13-valent vaccine doubled following vaccine roll out. Serotypes 6A and 19A were
most common among children with IPD. More and larger studies in different parts of Africa
are needed to thoroughly assess the effectiveness of PCV vaccination.
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